Evaxion A/S (EVAX) stock
EVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.78+0.01 (+0.36%)
Close on Nov 17, 2026Market cap $23.19MP/E –Yield –
Evaxion A/S total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Evaxion A/S's total debt was $5.31M at Jun 30, 2026. For fiscal 2025 it was $5.54M, down 32.2% from the year before. The highest annual figure on record is $8.65M in fiscal 2023.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.54M | -32.2% |
| FY2024 | Dec 31, 2024 | $8.17M | -5.6% |
| FY2023 | Dec 31, 2023 | $8.65M | +8.1% |
| FY2022 | Dec 31, 2022 | $8.00M | +583.8% |
| FY2021 | Dec 31, 2021 | $1.17M | -86.3% |
| FY2018 | Dec 31, 2018 | $8.57M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.31M | -36.9% |
| Q4 FY2025 | Dec 31, 2025 | $5.54M | -36.0% |
| Q2 FY2025 | Jun 30, 2025 | $9.22M | +12.0% |
| Q4 FY2024 | Dec 31, 2024 | $8.17M | +2.1% |
| Q2 FY2024 | Jun 30, 2024 | $8.42M | +12.9% |
| Q4 FY2023 | Dec 31, 2023 | $8.65M | +10.2% |
| Q2 FY2023 | Jun 30, 2023 | $8.23M | +603.2% |
| Q4 FY2022 | Dec 31, 2022 | $8.00M | +535.4% |
| Q2 FY2022 | Jun 30, 2022 | $7.46M | -13.0% |
| Q1 FY2022 | Mar 31, 2022 | $7.84M | – |
| Q4 FY2021 | Dec 31, 2021 | $1.17M | – |
| Q3 FY2021 | Sep 30, 2021 | $1.26M | – |
| Q4 FY2018 | Dec 31, 2018 | $8.57M | – |
See a number that looks wrong?